Adeona Pharmaceuticals (AMEX:AEN) (AEN)

Company Overview
Adeona Pharmaceuticals, Inc. ("Adeona") AMEX: AEN is a development-stage company from the pharmaceutical industry, working on the diagnosis, prevention and treatment of autoimmune and central nervous system diseases. The company's corporate strategy is to establish proprietary, clinical-stage drug candidates that have demonstrated clinical efficacy for the treatment of unmet medical diseases. The products focus on developing treatments for rheumatoid arthritis (RA), multiple sclerosis (MS), dry age-related macular degeneration (AMD) and fibromyalgia.
read more
Get Adobe Flash player

QUOTE

As of 03:45AM EDT May 23, 2012
Quote

COMPANY INFO

To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: 3930 Varsity Drive Ann Arbor, MI 48108 United States
Mailing Address: 3985 RESEARCH PARK DRIVE ANN ARBOR MI 48108
Phone: 734-332-7800
Fax: 734-332-7878
Website: http://www.adeonapharma.com

Company Details:

Symbol: AEN
SIC: 2834 - Pharmaceutical Preparations
State location: MI
Sector: -
State of Inc: DE
Employees: 10
Type: AMEX

LATEST ARTICLES

Adeona Pharmaceuticals (AMEX:AEN) Climbs Again with a New Member on Board Mar 30, 2010

Adeona Pharmaceuticals (AMEX:AEN) Climbs Again with a New Member on Board Around two weeks after the announcement that Jeff Lucero Riley, M.B.A. was joining its board of directors, Adeona Pharmaceuticals (AMEX:AEN) shares mark a fourth jump in price for the last three months.read more

LATEST STOCK PROMOTIONS

PennyOmega.com Stocks In Action on Monday! Nov 21, 2011, 13:18

    VRUS, Pharmasset, Inc.   ** Gilead Sciences, Inc. and VRUS reported that the companies have signed a definitive agreement under which Gilead will acquire VRUS for $137 per share in cash. The transaction values VRUS at approximately $11 billion   VRUS is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. VRUS’ primary focus is the development read more

Promoter: pennyomega.com Paying Party: UNKNOWN Max Profit: Pending Gain at close: Pending
Stock: Compensation: Unknown compensation Avg $ Volume for Period: UNKNOWN

PennyToBuck.com Stocks In Action on Monday! Nov 21, 2011, 13:07

      VRUS, Pharmasset, Inc.   ** Gilead Sciences, Inc. and VRUS reported that the companies have signed a definitive agreement under which Gilead will acquire VRUS for $137 per share in cash. The transaction values VRUS at approximately $11 billion   VRUS is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. VRUS’ primary focus read more

Promoter: penny to buck Paying Party: UNKNOWN Max Profit: Pending Gain at close: Pending
Stock: Compensation: Unknown compensation Avg $ Volume for Period: UNKNOWN

Stock-PR.com Stocks In Action on Monday! Nov 21, 2011, 13:05

      VRUS, Pharmasset, Inc.   ** Gilead Sciences, Inc. and VRUS reported that the companies have signed a definitive agreement under which Gilead will acquire VRUS for $137 per share in cash. The transaction values VRUS at approximately $11 billion   VRUS is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. VRUS’ primary focus read more

Promoter: Stock-pr Paying Party: UNKNOWN Max Profit: Pending Gain at close: Pending
Stock: Compensation: Unknown compensation Avg $ Volume for Period: UNKNOWN

ADEONA PHARMACEUTICALS (AMEX:AEN) (AEN) MESSAGE BOARD

Post # Subject Re Name Date
There are no comments.

Type the characters that you see in the box (5 characters).

This is a captcha-picture.
Get Adobe Flash player